PMID- 32754318
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Sep
TI  - Multiple endocrine neoplasia type 1 in patients with gastroenteropancreatic 
      neuroendocrine tumors: An opportunity for early diagnosis and appropriate 
      management.
PG  - 4
LID - 10.3892/mco.2020.2074 [doi]
LID - 4
AB  - Gastroenteropancreatic neuroendocrine tumors (GEPNET) are rare tumors that may be 
      sporadic or develop as part of multiple endocrine neoplasia type 1 syndrome 
      (MEN1). The aim of the present study was to report the experience of a Brazilian 
      multidisciplinary outpatient neuroendocrine tumor clinic regarding the clinical 
      diagnosis of MEN1 in a cohort of GEPNET patients. Patient data, including 
      clinical characteristics and the lag time from the onset of symptoms to diagnosis 
      of the first tumor, and further lag time until the diagnosis of MEN1, were 
      retrospectively reviewed. Among 44 GEPNET patients, 6 had a clinical diagnosis of 
      MEN1. Primary hyperparathyroidism and GEPNET were present in all patients in the 
      cohort, and pituitary neuroendocrine tumors were present in 33.3%. The median 
      time interval from the onset of initial symptoms to the diagnosis of the first 
      tumor was 42 months (range, 0-204 months). The median time interval between the 
      diagnosis of the first tumor and the diagnosis of MEN1 was 22 months (range, 
      1-109 months). The prolonged lag time between the onset of initial symptoms and 
      MEN1 diagnosis may result in substantial morbidity and loss of opportune 
      interventions for the patients. Therefore, greater efforts should be made to 
      shorten these times and improve the care of patients with MEN1.
CI  - Copyright (c) 2020, Spandidos Publications.
FAU - Pereira Brabo, Eloa
AU  - Pereira Brabo E
AD  - Oncology Unit and Neuroendocrine Section, Clementino Fraga Filho University 
      Hospital, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.
FAU - Barbosa Moraes, Aline
AU  - Barbosa Moraes A
AD  - Department of Internal Medicine, Endocrine Unit, Medical School and Clementino 
      Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de 
      Janeiro 21941-913, Brazil.
FAU - Dos Santos Marijuan Cabezas, Bethania Soares
AU  - Dos Santos Marijuan Cabezas BS
AD  - Oncology Unit and Neuroendocrine Section, Clementino Fraga Filho University 
      Hospital, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.
FAU - Vieira Neto, Leonardo
AU  - Vieira Neto L
AD  - Department of Internal Medicine, Endocrine Unit, Medical School and Clementino 
      Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de 
      Janeiro 21941-913, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC7391838
OTO - NOTNLM
OT  - delay in diagnosis
OT  - gastroenteropancreatic neuroendocrine tumor
OT  - multiple endocrine neoplasia type 1
OT  - pituitary adenoma
OT  - pituitary neuroendocrine tumor
OT  - primary hyperparathyroidism
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
PMCR- 2020/06/18
CRDT- 2020/08/06 06:00
PHST- 2019/10/20 00:00 [received]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
PHST- 2020/06/18 00:00 [pmc-release]
AID - MCO-0-0-02074 [pii]
AID - 10.3892/mco.2020.2074 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2020 Sep;13(3):4. doi: 10.3892/mco.2020.2074. Epub 2020 Jun 18.